Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Calliditas Therapeutics AB (publ) stock logo
CALT
Calliditas Therapeutics AB (publ)
$40.00
$40.00
$15.25
$43.00
$1.19B1.7710,339 shsN/A
Dicerna Pharmaceuticals, Inc. stock logo
DRNA
Dicerna Pharmaceuticals
$38.22
$38.12
$19.06
$40.14
$2.99B0.81.34 million shsN/A
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
$57.77
0.0%
$51.05
$1.16
$14.10
$2.50B-0.12189,291 shs672,319 shs
MorphoSys AG stock logo
MOR
MorphoSys
$18.96
$18.96
$4.18
$19.50
$2.86B1.21.02 million shsN/A
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Calliditas Therapeutics AB (publ) stock logo
CALT
Calliditas Therapeutics AB (publ)
0.00%0.00%0.00%0.00%+1.83%
Dicerna Pharmaceuticals, Inc. stock logo
DRNA
Dicerna Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
-0.03%+1.51%+15.33%+37.01%+20.56%
MorphoSys AG stock logo
MOR
MorphoSys
0.00%0.00%0.00%0.00%+0.58%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Calliditas Therapeutics AB (publ) stock logo
CALT
Calliditas Therapeutics AB (publ)
N/AN/AN/AN/AN/AN/AN/AN/A
Dicerna Pharmaceuticals, Inc. stock logo
DRNA
Dicerna Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
MorphoSys AG stock logo
MOR
MorphoSys
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Calliditas Therapeutics AB (publ) stock logo
CALT
Calliditas Therapeutics AB (publ)
0.00
N/AN/AN/A
Dicerna Pharmaceuticals, Inc. stock logo
DRNA
Dicerna Pharmaceuticals
0.00
N/AN/AN/A
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
0.00
N/AN/AN/A
MorphoSys AG stock logo
MOR
MorphoSys
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Calliditas Therapeutics AB (publ) stock logo
CALT
Calliditas Therapeutics AB (publ)
$1.60B0.74N/AN/A$1.06 per share37.74
Dicerna Pharmaceuticals, Inc. stock logo
DRNA
Dicerna Pharmaceuticals
$164.31M18.17N/AN/A$1.84 per share20.77
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
N/AN/AN/AN/A$2.89 per shareN/A
MorphoSys AG stock logo
MOR
MorphoSys
$238.28M11.99N/AN/A$0.35 per share54.17
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Calliditas Therapeutics AB (publ) stock logo
CALT
Calliditas Therapeutics AB (publ)
-$43.96M-$1.85N/A8.68N/A-30.18%-212.04%-27.96%N/A
Dicerna Pharmaceuticals, Inc. stock logo
DRNA
Dicerna Pharmaceuticals
-$112.75M-$1.63N/AN/AN/A-64.53%-103.08%-16.58%N/A
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
-$71.87M-$1.00N/AN/AN/AN/A-38.78%-35.88%N/A
MorphoSys AG stock logo
MOR
MorphoSys
-$205.35M-$3.48N/AN/AN/A-226.79%-694.31%-22.55%N/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Calliditas Therapeutics AB (publ) stock logo
CALT
Calliditas Therapeutics AB (publ)
N/AN/AN/AN/AN/A
Dicerna Pharmaceuticals, Inc. stock logo
DRNA
Dicerna Pharmaceuticals
N/AN/AN/AN/AN/A
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
N/AN/AN/AN/AN/A
MorphoSys AG stock logo
MOR
MorphoSys
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Calliditas Therapeutics AB (publ) stock logo
CALT
Calliditas Therapeutics AB (publ)
9.44
2.69
2.59
Dicerna Pharmaceuticals, Inc. stock logo
DRNA
Dicerna Pharmaceuticals
N/A
2.46
2.46
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
N/A
71.49
71.49
MorphoSys AG stock logo
MOR
MorphoSys
4.98
1.38
1.38

Institutional Ownership

CompanyInstitutional Ownership
Calliditas Therapeutics AB (publ) stock logo
CALT
Calliditas Therapeutics AB (publ)
2.83%
Dicerna Pharmaceuticals, Inc. stock logo
DRNA
Dicerna Pharmaceuticals
78.91%
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
75.42%
MorphoSys AG stock logo
MOR
MorphoSys
18.38%
CompanyEmployeesShares OutstandingFree FloatOptionable
Calliditas Therapeutics AB (publ) stock logo
CALT
Calliditas Therapeutics AB (publ)
18029.79 million29.14 millionOptionable
Dicerna Pharmaceuticals, Inc. stock logo
DRNA
Dicerna Pharmaceuticals
30278.13 million70.16 millionOptionable
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
3043.33 million37.74 millionNot Optionable
MorphoSys AG stock logo
MOR
MorphoSys
730150.62 million150.55 millionNot Optionable

Recent News About These Companies

Novartis to shut MorphSys sites amid pelabresib delay
Novartis sheds MorphoSys staff, sites after pelabresib delay
Novartis shutters MorphoSys sites, lays off staff
Novartis raises mid-term sales guidance

Media Sentiment Over Time

Top Headlines

View All Headlines
Calliditas Therapeutics AB (publ) stock logo

Calliditas Therapeutics AB (publ) NASDAQ:CALT

$40.00 0.00 (0.00%)
As of 07/18/2025

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.

Dicerna Pharmaceuticals stock logo

Dicerna Pharmaceuticals NASDAQ:DRNA

Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson, and John J. Rossi in October 2006 and is headquartered in Lexington, MA.

Gemini Therapeutics stock logo

Gemini Therapeutics NASDAQ:GMTX

$57.77 -0.02 (-0.03%)
As of 07/18/2025

Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

MorphoSys stock logo

MorphoSys NASDAQ:MOR

$18.96 0.00 (0.00%)
As of 07/18/2025

MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.